ArticleKidney international reports2026
Randomized Controlled Study of Sirolimus-Coated Balloons for Dysfunctional Hemodialysis Fistulas.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04409912 (SIroliMus Coated angioPlasty Versus Plain Balloon Angioplasty in the tREatment of dialySis acceSs dysfunctION), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SIroliMus Coated angioPlasty Versus Plain Balloon Angioplasty in the tREatment of dialySis acceSs dysfunctION (IMPRESSION)
Who cites it
1 citing paper in PubMed.
- Flowing Fistulas: Update on Strategies to Maintain Arteriovenous Fistula Patency.Kidney international reports · 2026Article
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Restenosis following balloon angioplasty remains a major cause of arteriovenous fistula (AVF) dysfunction in patients receiving maintenance hemodialysis. We evaluated whether the use of sirolimus-coated angioplasty balloons (SCBs) improves access circuit primary patency (ACPP) in patients with dysfunctional, nonthrombosed AVFs. Methods: In this investigator-initiated, multicenter, single-blinded, randomized controlled trial (ClinicalTrials.gov identifier: NCT04409912), we enrolled 170 patients from 3 tertiary teaching hospitals in Singapore. Patients with dysfunctional AVFs, including those with single or multiple stenotic lesions within the access circuit, were included. Following successful plain balloon angioplasty (PBA) (< 30% residual stenosis on digital subtraction angiography), the patients were randomly assigned, using a centralized web-based system, to receive additional treatment with SCB ( Results: In both intention-to-treat (ITT) and per-protocol (PP) analyses, 6-month ACPP was significantly higher in the SCB group than in the placebo group ( Conclusion: Use of SCB following successful PBA improved 6-month ACPP in patients with dysfunctional AVFs, including those with multiple stenotic lesions. Short-term safety findings were reassuring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.